Market Place
Sourcing Support
Biogen lays off 100-plus Reata staffers
12 Oct 2023 //
FIERCE PHARMA
Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.
21 Sep 2023 //
BUSINESSWIRE
How Biogen courted Reata for $7.3B—and outbid a competitor
15 Aug 2023 //
FIERCE PHARMA
Biogen to buy Reata for $6.5 bln to bulk up rare disease portfolio
29 Jul 2023 //
HEALTH ET
Biogen to Acquire Reata Pharmaceuticals
28 Jul 2023 //
GLOBENEWSWIRE
Plano-based Reata Pharmaceuticals launches its first drug, Skyclarys
29 Jun 2023 //
DALLASNEWS
Reata Pharma Announces Approval of Prior Approval Supplement for SKYCLARY
27 Jun 2023 //
BUSINESSWIRE
Reata Pharmaceuticals Announces FDA Filing Acceptance of SKYCLARYS®
15 Jun 2023 //
BUSINESSWIRE
Reata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President
13 Jun 2023 //
BUSINESSWIRE
Reata Announces Participation in the Goldman Sachs 44th Healthcare Conference
06 Jun 2023 //
BUSINESSWIRE
Reata culls bardoxolone, ending decade of R&D on troubled kidney disease drug
11 May 2023 //
ENDPTS
Reata Announces 1Q 2023v YR and Provides Update Clinical Development Programs
10 May 2023 //
BUSINESSWIRE
Reata, Kyowa Kirin ax bardoxolone, ending 13-year saga
10 May 2023 //
FIERCE BIOTECH
Reata to Report 1Q 2023 FYR and to Provide an Update on Operational Progress
02 May 2023 //
BUSINESSWIRE
Reata Announces Participation in the Barclays Global Healthcare Conference
06 Mar 2023 //
BUSINESSWIRE
Why Reata Pharmaceuticals Stock Skyrocketed This Week
02 Mar 2023 //
PRESS RELEASE
FDA signs off on Reata`s Skyclarys for rare neurologic disorder
02 Mar 2023 //
FIERCE PHARMA
Reata obtains US nod for Friedreich`s ataxia drug Skyclarys
01 Mar 2023 //
BUSINESSWIRE
Reata : A loss of $2.22 per share anticipated for fourth quarter
24 Feb 2023 //
KALKINEMEDIA
Lilly Pulls EU Approval Application For Olumiant In COVID-19
19 Dec 2022 //
PINK SHEET
Lilly Pulls EU Approval Application For Olumiant In COVID-19
19 Dec 2022 //
PINK SHEET
Reata Pharmaceuticals Announces Participation in the Guggenheim 2022 Immunology
10 Nov 2022 //
BUSINESSWIRE
Reata Pharma Announces 3Q 2022 FYR and Provides an Update on Clinical DevP
08 Nov 2022 //
PRESS RELEASE
Reata Pharmaceuticals, Inc. to Report Third Quarter 2022 Financial Results
31 Oct 2022 //
BUSINESSWIRE
Reata Announces Presentations at International Congress for Ataxia Research 2022
20 Oct 2022 //
BUSINESSWIRE
FDA scraps AdComm for Reata`s rare disease candidate
14 Oct 2022 //
FIERCEBIOTECH
Reata Pharma Shares Rise 18%; FDA Doesn`t Plan Advisory Meeting For NDA
14 Oct 2022 //
FIRSTWORLDPHARMA
Reata Announces that the FDA Does Not Plan to Hold an Advisory Committee
13 Oct 2022 //
BUSINESSWIRE
Reata Announces Participation in the Citi 17th Annual BioPharma Conference
06 Sep 2022 //
BUSINESSWIRE
Reata has wait for FDA ataxia drug decision delayed by 3 months
10 Aug 2022 //
FIERCEBIOTECH
Karuna`s schizophrenia drug passes PhIII test, will head to FDA in mid-2023
09 Aug 2022 //
ENDPTS
Reata continues to hit FDA roadblocks with its Friedreich’s ataxia candidate
09 Aug 2022 //
ENDPTS
Reata Pharma Announces Second Quarter 2022 Financial Results
08 Aug 2022 //
PRESS RELEASE
Reata Pharma to Report 2nd Quarter 2022 Financial Results
01 Aug 2022 //
BUSINESSWIRE
Reata Appoints Steven W. Ryder, M.D. to its Board of Directors
11 Jul 2022 //
BUSINESSWIRE
Reata Pharma`s FDA Filing Acceptance and Priority Review for Omaveloxolone
26 May 2022 //
BUSINESSWIRE
Reata Pharma Announces First Quarter 2022 Financial Results
10 May 2022 //
BUSINESSWIRE
Reata Pharma to Report First Quarter 2022 Financial Results
02 May 2022 //
BUSINESSWIRE
Reata`s Rolling Submission of NDA for Omaveloxolone in Friedreich’s Ataxia
31 Mar 2022 //
BUSINESSWIRE
FDA rejects Reata`s kidney drug after adcomm voted unanimously against it
01 Mar 2022 //
ENDPTS
Reata Pharma Announces Fourth Quarter and Full Year 2021 Financial Results
28 Feb 2022 //
PRESS RELEASE
Reata slips as FDA rejects kidney disease therapy
26 Feb 2022 //
SEEKING ALPHA
Reata To Report Q4 and Full Year 2021 Financial Results on Feb 28, 2022
18 Feb 2022 //
BUSINESSWIRE
RETA Investors Have Opportunity to Lead Reata Pharma Securities Fraud Lawsuit
07 Feb 2022 //
PRNEWSWIRE
Reata Initiates Rolling Submission of NDA with FDA for Omaveloxolone
31 Jan 2022 //
BUSINESSWIRE
FDA slams Reata`s kidney drug as ineffective ahead of adcomm meeting
06 Dec 2021 //
ENDPTS
FDA Grants FTD to Reata`s Omaveloxolone for Friedreich’s Ataxia
18 Nov 2021 //
BUSINESSWIRE
Reata Announces Q3 2021 Financial Results and Provides Update
08 Nov 2021 //
BUSINESSWIRE
Reata Submits MKTAuthorization Application to the EMA for Bardoxolone Methyl
28 Oct 2021 //
BUSINESSWIRE
Reata Pharmaceuticals NDA Submission for Omaveloxolone in First Quarter of 2022
30 Sep 2021 //
BUSINESSWIRE
Reata Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results
09 Aug 2021 //
BUSINESSWIRE
Reata Pharmaceuticals, Inc. to Report Second Quarter 2021 Financial Results
02 Aug 2021 //
BUSINESS WIRE
Reata Pharmaceuticals Announces Presentations at Upcoming Medical Conferences
29 Mar 2021 //
BLOOMBERG
Reata , Inc. Submits NDA for Company’s Lead Program: Bardoxolone
01 Mar 2021 //
GLOBENEWSWIRE
Reata Pharmaceuticals, Inc. Announces Pricing of Class A Common Stock Offering
01 Dec 2020 //
GLOBENEWSWIRE
FDA requests new trial for Reata`s Friedreich`s ataxia program; J&J`s
25 Nov 2020 //
ENDPTS
Reata Provides Update on Omaveloxolone Program for Patients
24 Nov 2020 //
GLOBENEWSWIRE
Reata Announces +VE Results From 2y of the Pivotal Ph3 Study of Bardoxolone
09 Nov 2020 //
PRESSRELEASE
Reata Announces the Presentation of the Pivotal MOXIe Part 2 Study
03 Sep 2020 //
GLOBENEWSWIRE
Reata suggests Friedreich`s ataxia program could be delayed, sending stock plunging
11 Aug 2020 //
ENDPTS
